StockNews.AI
ILMN
StockNews.AI
176 days

Illumina transforms multiomic research with new technologies to unlock deeper understanding of biology

1. Illumina expands multiomics portfolio across genomics, spatial, single cell, CRISPR, and methylation. 2. New roadmap innovations leverage powerful sequencers to deliver unmatched quality and scalability. 3. Integrated multimodal data analytics streamline workflows for accelerated precision healthcare research. 4. Commercial launches planned for 2025-2026 promise breakthrough market opportunities for ILMN.

10m saved
Insight
Article

FAQ

Why Bullish?

The innovation pipeline underscores ILMN's leadership; previous similar announcements boosted stock. Investors may view these disruptive solutions as a driver for revenue expansion and market differentiation.

How important is it?

This comprehensive portfolio expansion directly enhances ILMN's growth strategy and competitive edge. The multiomics focus is expected to drive investment interest and long-term revenue generation.

Why Long Term?

The timeline for product launches (2025-2026) and the strategic positioning in multiomics indicate lasting market influence. Similar past transitions in biotech led to sustained performance improvements over several years.

Related Companies

PACBONT
Company expands multiomics portfolio with new roadmap technologies spanning genomics, spatial, single cell, CRISPR, and methylation, as well as a new multimodal data analysis platform Built on Illumina's powerful sequencers, new, disruptive omics solutions surpass industry standards for quality, scale, accuracy, and replicability SAN DIEGO, Feb. 24, 2025 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) has unveiled a series of roadmap innovations, establishing the industry's largest portfolio of omics solutions and sequencing applications. The solutions – spanning genomics, spatial transcriptomics, single cell analysis, CRISPR technologies, epigenetics, and data analytics software – will enable researchers to derive breakthrough insights around the drivers of disease. The new omics solutions surpass industry standards for scale, accuracy, and reliability because they are built on Illumina's powerful sequencers, known for unmatched quality, consistency, and accuracy. The expanded multiomics portfolio will be presented today at the Advances in Genome Biology and Technology (AGBT) General Meeting. "Illumina is the backbone of innovation for our industry, and we're bringing disruptive, new solutions at a scale that only Illumina can deliver," said Jacob Thaysen, CEO of Illumina. "Illumina has paved the way for genomic breakthroughs, and now we are committed to accelerating advances on all frontiers of multiomics. Our technologies will help researchers gain a more complete understanding of biology, accelerating the translation of data into insights that can truly unlock precision health care." "Illumina is doing what we do best: breaking new ground and setting the standard," said Steve Barnard, PhD, chief technology officer of Illumina. "Just as researchers have come to rely on an accurate, complete and comprehensive view of the genome, Illumina is now bringing the same attributes to the entire range of multiomics exploration, with the complete workflows needed to ensure value and usability. These solutions represent a leap forward in discovery, and we can't wait to bring these solutions into more labs." Illumina's announcements at AGBT drive new scale, quality in multiomic discovery Illumina's AGBT Gold Sponsor Workshop today will showcase the latest advances across a range of multiomic capabilities enabled on Illumina's sequencing platforms and supported by its new multimodal data analysis platform. The updates illustrate Illumina's continued commitment to provide customers with end-to-end solutions that streamline and simplify workflows, and its growing portfolio of multiomics offerings, which includes Illumina Single Cell and Illumina Protein Prep. Stephen Kingsmore, MD, DSc, president and CEO of Rady Children's Institute for Genomic Medicine, will share his experience with constellation mapped read technology and the potential impact for comprehensive, rapid WGS that can enable earlier diagnosis of genetic and rare diseases. "Constellation's ability to provide a high-resolution view of structural variation — including the most common cause of hemophilia A in boys, which was impossible with standard methods — is an impressive advance in genome sequencing," said Kingsmore. "Previously these variants had to be identified by custom one-off assays that typically took a month or more. Constellation makes it possible to go from rapid sequencing to insights in just over a day." Kingsmore will also present an abstract in a concurrent session, "A novel WGS workflow to aid in the design of allele-specific antisense oligonucleotides for patients with rare genetic conditions," on Monday, February 24, 4:30–4:50 p.m. ET. Products based on constellation mapped reads technology are expected to be commercially available in 2026. The solution is expected to launch by the end of 2025 with three new kit formats that are compatible with 10,000, 100,000, and 1 million cells per sample, facilitating targeted studies with 100 guide RNA (gRNA) sequences to full genome-scale discovery with over 10,000 gRNAs per experiment. The solution leverages new improvements on the foundational Fluent PIPseq technology for dual measurement of CRISPR gRNA sequences and 3' RNA gene expression in the same assay. The gRNA direct capture provides a more cost-effective workflow, improved sensitivity, and higher scalability than current single-cell kits. The solution will provide single-cell readout of CRISPR activation, inactivation, or targeted gene editing Perturb-seq experiments for exciting applications, including cell atlasing or drug screening research. The kits are compatible across Illumina sequencers, and the workflow includes DRAGEN Single Cell RNA Analysis for CRISPR gRNA screening through Illumina software. Planned for launch in 2026, Illumina's solution will provide 5-base insights into the genome, cell-free DNA, or targeted assays through a single library preparation, sequencing, and analysis run, enabling deeper understanding of the genome while remaining cost effective. Currently, industry barriers to adoption of 5-base solutions include cost, usability, and lack of reliable analytics solutions. Existing offerings for simultaneous DNA and methylation detection are limited in the accuracy they can achieve for both genetic and epigenetic data. Illumina's solution aims to address these barriers by delivering the easiest, most cost effective end-to-end solution for high-accuracy detection of both genetic variants and methylation in a single assay. Early access customer data will be presented by Bekim Sadikovic, PhD, director of the Molecular Genetics Laboratory at London Health Sciences Centre Research Institute, in a concurrent session on Tuesday, February 25, 9:10–9:30 p.m. ET, titled, "Novel integrated platform for simultaneous detection of genetic variants and epigenetic signatures in rare undiagnosed genetic diseases." Spatial transcriptomics allows researchers to explore biological interactions at the cellular level. For instance, through "cell atlasing," which maps the detailed arrangement of cells, researchers can gain novel insights into complex tissue structures that affect disease. Illumina's spatial technology will fuel life sciences breakthroughs ranging from tumor microenvironments to disease pathways, neurobiology, immuno-oncology, and more. As a complete end-to-end solution, it will also deliver the highest value for single-cell and spatial researchers at a more affordable price point. Commercial launch of the technology is planned for 2026. The company's Gold Sponsor Workshop at AGBT will be held February 24, 12–1:30 p.m. ET. Illumina will demonstrate its end-to-end workflows throughout the AGBT conference in Osprey Lounge 1. To learn more about Illumina's multiomic solutions, visit illumina.com/innovation. Use of forward-looking statements This release may contain forward-looking statements that involve risks and uncertainties. Among the important factors to which our business is subject that could cause actual results to differ materially from those in any forward-looking statements are: (i) challenges inherent in developing and launching new products and services, including modifying and scaling manufacturing operations, and reliance on third-party suppliers for critical components; (ii) our ability to manufacture robust instrumentation and consumables; and (iii) the acceptance by customers of our newly launched products, which may or may not meet our and their expectations, together with other factors detailed in our filings with the Securities and Exchange Commission, including our most recent filings on Forms 10-K and 10-Q, or in information disclosed in public conference calls, the date and time of which are released beforehand. We undertake no obligation, and do not intend, to update these forward-looking statements, to review or confirm analysts' expectations, or to provide interim reports or updates on the progress of the current quarter. About Illumina Illumina is improving human health by unlocking the power of the genome. Our focus on innovation has established us as a global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical, and applied markets. Our products are used for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. To learn more, visit illumina.com and connect with us on X, Facebook, LinkedIn, Instagram, TikTok, and YouTube. Contacts Investors:Salli Schwartz858-291-6421[email protected] Media:Christine Douglass[email protected] SOURCE Illumina, Inc.

Related News